Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
IGF is a peptide hormone that plays a crucial role in cell growth, proliferation, and differentiation. It is structurally similar to insulin and exerts its effects by binding to the IGF receptor, activating intracellular signaling pathways involved in cellular growth and metabolism. IGF is primarily used in the treatment of growth hormone deficiency (GHD) in both pediatric and adult patients. It is also utilized in certain cases of pediatric and adult short stature, muscle wasting disorders, and age-related diseases. According to WHO, growth hormone deficiency affects approximately 1 in 4,000 children worldwide. In Europe, the prevalence of GHD ranges from 1 in 3,000 to 1 in 10,000 children, with variations among countries. In the United States, an estimated 6,000 to 10,000 children have GHD. Moreover, short stature affects around 3% of children globally, with variations based on age, gender, and ethnic background. Age-related diseases, including osteoporosis and sarcopenia, are significant health concerns in the aging population. According to the European Commission, osteoporosis affects approximately 22 million women and 5.5 million men in the European Union. In the United States, over 10 million individuals have osteoporosis, and about 44 million adults aged 50 and older are affected by osteoporosis or low bone mass.
The growth drivers of the IGF market include increasing awareness of its therapeutic potential, advancements in biotechnology and genetic engineering, growing geriatric population, and favorable reimbursement policies. Companies such as Recordati, Eli Lilly, Generic mfg., Takeda, Ipsen, BMS, Viridian Therap, Oak Hill Bio, AstraZeneca, Axelar, Merck (MSD), Biogen, TriAct Therap, CSPC Pharma, Debiopharm, Silver Creek Pharma, Innovent Biologics, Kyowa Kirin, Lirum Therap, Exelixis cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Eli Lilly is currently conducting a clinical trial of the drug IMC-A12 for the treatment of idiopathic adenocarcinoma.
Key Developments:
Approved IGF molecules
IGF Pipeline Molecules
Clinical Activity and Development of IGF
In the IGF space, more than 30 companies are conducting more than 800 clinical trials in this category of drugs. For instance,
|
Product Name |
Total Studies |
|
Cixutumumab (IMC A12) |
45 |
|
Ganitumab (AMG 479) |
30 |
|
Linsitinib (ASP7487) |
27 |
|
Dalotuzumab (MK 0646) |
25 |
|
Figitumumab (CP-751,871) |
25 |
|
Xentuzumab (BI-836845) |
9 |
|
BMS-754807 |
7 |
|
VRDN-001 |
7 |
|
Dusigitumab (MEDI-573) |
5 |
|
Picropodophyllin (AXL1717) |
5 |
|
Robatumumab (SCH 717454) |
4 |
|
BIIB022 |
3 |
|
EP-201 |
3 |
|
Atesidorsen (ATL1103) |
3 |
|
Istiratumab (MM-141) |
3 |
|
IBI311 |
2 |
|
KW-2450 |
2 |
|
LX-101 |
2 |
|
XL228 |
2 |
|
Conteltinib (SY-707) |
2 |
Insulin-like Growth Factor-1 (IGF) is being investigated as a potential therapeutic target for various medical conditions. Its role in promoting cell growth, proliferation, and differentiation makes it a candidate for indications such as growth hormone deficiency, pediatric and adult short stature, muscle wasting disorders, and age-related diseases. Additionally, IGF's involvement in neuroprotection, tissue repair, and immune modulation has led to research exploring its potential applications in neurological disorders, wound healing, and autoimmune diseases. Despite the challenges, ongoing studies aim to further elucidate the therapeutic potential of IGF and develop targeted interventions for a range of indications.
The global IGF market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US market for Insulin-like Growth Factor-1 (IGF) is expected to witness significant growth in the coming years. The high prevalence of growth hormone deficiency, pediatric and adult short stature, and muscle wasting disorders in the country drives the demand for IGF as a potential therapeutic option. Additionally, the aging population and the rising incidence of age-related diseases present a growing market for IGF in the US. Moreover, advancements in biotechnology and pharmaceutical research, along with increasing investment in healthcare infrastructure, further contribute to the expansion of the IGF market in the region. The growth of the IGF market is primarily driven by several factors. Firstly, the increasing awareness and understanding of IGF's role in promoting cell growth, tissue repair, and immune modulation have bolstered its adoption as a therapeutic option across various indications. Secondly, the continuous advancements in biotechnology and genetic engineering techniques have facilitated the development and production of IGF with improved efficacy and safety profiles. Furthermore, the expanding geriatric population and the growing prevalence of age-related diseases have created a substantial market demand for IGF. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for IGFs. These countries are increasingly adopting IGFs due to their efficacy and potential to improve patient outcomes. On the other hand, the IGF market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the IGF market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
IGF drugs are used in the management of neurological disorders, wound healing, and autoimmune diseases.
The growth drivers of the IGF market include increasing awareness of its therapeutic potential, advancements in biotechnology and genetic engineering, growing geriatric population, and favorable reimbursement policies.
The major players in this space are Recordati, Eli Lilly, Generic mfg., Takeda, Ipsen, BMS, Viridian Therapy, Oak Hill Bio, AstraZeneca, Axelar, Merck (MSD), Biogen, TriAct Therap, CSPC Pharma, Debiopharm, Silver Creek Pharma, Innovent Biologics, Kyowa Kirin, Lirum Therap, Exelixis.
The market for Insulin-like Growth Factor-1 (IGF) is restrained by limited regulatory approvals and high production costs, limiting its accessibility and affordability for patients and healthcare providers. Additionally, the potential adverse effects and concerns about its long-term safety profile also pose challenges for widespread adoption in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.